...
首页> 外文期刊>Risk analysis >Animal Antibiotic Use and Human Health: No Expert Judgment is Needed to Determine that Reducing Cases Reduces Risk
【24h】

Animal Antibiotic Use and Human Health: No Expert Judgment is Needed to Determine that Reducing Cases Reduces Risk

机译:动物抗生素的使用和人类健康:无需专家判断就可以确定减少病例的发生可以降低风险

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In his comments on our Rapid Risk Rating Technique (RRRT), Dr. Claycamp states that "Cox and Popken were silent on the pivotal expert judgment subsumed in their method: quality weights for illnesses caused by antimicrobial-resistant and antimicrobial-sensitive microbes are tacitly assumed to be equal." However, contrary to this comment, we explicitly provide separate quality weights for antimicrobial-resistant and antimicrobial-sensitive illnesses (with different values, based on QALYs lost per illness, illustrated in our article). Thus, our model already addresses Dr. Claycamp's central concern. Moreover, since withdrawing macrolides and fluoroquinolones from use as animal antibiotics is projected to cause more of both types of illnesses—antimicrobial-resistant and antimicrobial-sensitive—than continuing to use them would, our conclusion that such withdrawals would be poor public health policy is completely robust to changes in the quality weights. Our human health impacts assessment is therefore indeed immune from the "expert judgments in risk management" discussed by Dr. Claycamp.
机译:Claycamp博士在对我们的快速风险评估技术(RRRT)的评论中说:“ Cox和Popken对他们的方法所包含的关键专家判断保持沉默:对由抗药性和对微生物敏感的微生物引起的疾病的质量权重是默认的假定是相等的。”但是,与该评论相反,我们明确为抗药性和抗药性疾病提供了单独的质量权重(根据每次疾病损失的QALYs,具有不同的值,如本文所述)。因此,我们的模型已经解决了Claycamp博士的核心问题。此外,由于退出大环内酯类和氟喹诺酮类药物作为动物抗生素,预计会引起更多的两种疾病(抗药性和抗微生物药性),而不是继续使用它们,因此我们得出的结论是,此类撤出将是不良的公共卫生政策。对质量权重的变化完全稳定。因此,我们的人类健康影响评估确实不受Claycamp博士讨论的“风险管理专家判断”的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号